Clinical Research Directory
Browse clinical research sites, groups, and studies.
Long-Term Safety of Pirtobrutinib in Participants With Previously Treated Types of Blood Cancers
Sponsor: Eli Lilly and Company
Summary
The purpose of this study is to find out more about the long-term safety of pirtobrutinib in participants with previously treated types of blood cancer. Participants must have chronic lymphocytic leukemia, small lymphocytic lymphoma, or non-Hodgkins lymphoma. The study is open to those who completed the original study - J2N-MC-JZNJ (NCT04849416) and continue to benefit from treatment. Treatment will be given every 12 weeks and this study is expected to last about 5 years.
Official title: Long-Term Safety of Pirtobrutinib in Participants From Study J2N-MC-JZNJ With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
13
Start Date
2025-08-07
Completion Date
2030-05
Last Updated
2026-01-21
Healthy Volunteers
No
Interventions
Pirtobrutinib
Administered orally.
Locations (6)
Beijing Cancer hospital
Beijing, China
Sun Yat-sen University Cancer Center
Guangzhou, China
Harbin Medical University Cancer Hospital
Harbin, China
Shanghai East Hospital
Shanghai, China
Blood Institute of the Chinese Academy of Medical science
Tianjin, China
Union Hospital Tongji Medical College Huazhong University of Science and Technology
Wuhan, China